Prime MedicinePRME -11.01%23 EV-to-EBIT is -3.20 as of Jul. 12, 2026. GuruFocus rates PRME with a GF Score™ of 23/100. The stock has 5 warning signs investors should review. Among 365 Biotechnology companies, Prime Medicine ranks worse than 273972.33% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Prime Medicine's Enterprise Value for the quarter that ended in Mar. 2026 was $607.56 Mil.
Prime Medicine's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-206.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prime Medicine EV-to-EBIT Related Terms
Prime Medicine EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Prime Medicine's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prime Medicine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Prime Medicine's EV-to-EBIT falls into.
Prime Medicine's current Enterprise Value is $661.75 Mil.
Prime Medicine's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-206.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prime Medicine (PRME) has a EV-to-EBIT of -3.20 as of Jul. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Prime Medicine and its competitors. According to the industry distribution chart, Prime Medicine ranks #999999 out of 365 companies in the Biotechnology industry.
Is Prime Medicine's EV-to-EBIT too high?
Prime Medicine's current EV-to-EBIT is -3.20. Based on the distribution chart, Prime Medicine ranks #999999 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prime Medicine has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's EV-to-EBIT compare to EIKN and CRMD?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #999999 out of 365 companies for EV-to-EBIT. This places Prime Medicine in the lower half of its industry. The industry median EV-to-EBIT is 14.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.29, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Prime Medicine and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current EV-to-EBIT is -3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current EV-to-EBIT of -3.20. The current EV-to-EBIT is -3.20. Prime Medicine's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Prime Medicine (PRME), the current EV-to-EBIT is -3.20 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
23GF Score
Get the complete analysis for PRME
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
